Myotonic dystrophy
RecruitingA study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1
A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1
- Disease:Myotonic dystrophy
- Substances:Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 OligonucleotideSodium Chloride Ph. Eur.+1
The Netherlands- Participants:0–17 years · 18–64 years
- Substances:Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide
- Sponsor:Dyne Therapeutics Inc.









